Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $964.1M | $947.7M | $985.8M | $253.6M | $240.3M | |
| Gross Profit | $287.9M | $193.9M | $207.3M | $54.3M | $43.1M | |
| Operating Income | $141M | $16.1M | $38.2M | $5M | $858.9K | |
| EBITDA | $183.6M | $68.8M | $94.7M | $20.7M | $14.7M | |
| Diluted EPS | $1.58 | $0.15 | $0.20 | $0.05 | -$0.21 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $303.3M | $420.2M | $440.7M | $350.1M | $356.7M | |
| Total Assets | $687.5M | $771.1M | $974.2M | $1.3B | $1.3B | |
| Current Liabilities | $158.3M | $157.2M | $140.5M | $183.5M | $163.7M | |
| Total Liabilities | $242M | $230.2M | $242.8M | $450.6M | $491.3M | |
| Total Equity | $445.6M | $540.9M | $731.4M | $840.3M | $765.7M | |
| Total Debt | $81.6M | $71.7M | $84.2M | $251.7M | $326.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $143M | $52.6M | $68.7M | $3.2M | $13.6M | |
| Cash From Investing | -$148.9M | -$359.9M | -$21.7M | -$1.5M | -$8.8M | |
| Cash From Financing | -$9.6M | $165.5M | -$54.9M | -$13.4M | -$21.3M | |
| Free Cash Flow | $129.4M | $45.2M | $59.9M | $1.8M | $9.4M | |
Endava Plc engages in the provision of next-generation technology services, enabling its clients to accelerate growth, tackle complex challenges and thrive in evolving markets. it provides its clients with tailor-made solutions at every stage of their digital transformation, regardless of industry, region or scale. The company was founded by John Edward Cotterell in February 2000 and is headquartered in London, the United Kingdom.
In the current month, DAVA has received 3 Buy ratings 6 Hold ratings, and 0 Sell ratings. The DAVA average analyst price target in the past 3 months is $10.70.
According to analysts, the consensus estimate is that Endava Plc share price will rise to $10.70 per share over the next 12 months.
Analysts are divided on their view about Endava Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Endava Plc is a Sell and believe this share price will drop from its current level to $7.53.
The price target for Endava Plc over the next 1-year time period is forecast to be $10.70 according to 9 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Endava Plc is a Hold. 6 of 9 analysts rate the stock a Hold at this time.
You can purchase shares of Endava Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Endava Plc shares.
Endava Plc was last trading at $6.54 per share. This represents the most recent stock quote for Endava Plc. Yesterday, Endava Plc closed at $6.53 per share.
In order to purchase Endava Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.